Lilly recently announced news that could solve a big problem.
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
These two pharma stocks have followed distinct paths of late. Which is the better investment?
Altimmune has a modest market cap but an incredibly promising GLP-1 drug.
Low risk and high-reward potential? These stocks could offer both.
Structure Therapeutics is developing an oral weight-loss drug, which could allow it to gain traction in a rapidly expanding addressable market.
These stocks have taken different paths to where they are today, but both have been exceptional investments.
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.
The S&P 500 Index ($SPX ) (SPY ) this morning is down -0.22%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.16%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.55%. US stock indexes...
The S&P 500 Index ($SPX ) (SPY ) this morning is up +0.42%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.33%. US stock indexes this morning...